HOME

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this
announcement, makes no representation as to its accuracy or completeness and expressly
disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon
the whole or any part of the contents of this announcement.
Shandong Weigao Group Medical Polymer Company Limited*(a joint stock limited company
incorporated in the People’s Republic of China with limited liability)
(Stock Code:8199)
NOTICE OF THE EXTRAORDINARY GENERAL MEETING
NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “EGM”) of
Shandong Weigao Group Medical Polymer Company Limited*
(the “Company”) will be held at 8:30 a.m. on 28 September
2004 at the registered office of the company at 35 Yan Tai West Road, Weihai, Shandong
Province, PRC for the purpose of considering the following resolutions:
ORDINARY RESOLUTIONS
1. “THAT the board of directors of the Company (the “Board”) be hereby approved to
propose an interim dividend of RMB0.007 per share to be distributed to all the
shareholders whose names appeared on the register of members of the Company at 4:00
p.m. on 5 October 2004.”
2. “THAT subject to the approval of the relevant shareholders meeting of Weihai Jierui
Medical Products Company Limited (“Jierui Subsidiary”), the Board be hereby
approved to inject its portion of capital of RMB19.2 million to Jierui Subsidiary on a
pro rata basis. The equity interest of the existing shareholders remains unchanged.
3. “THAT subject to the approval of the relevant shareholders meeting of JW Medical
Systems Corporation (“JW Medical”), the Board be hereby approved to inject its portion
of capital of RMB9 million to JW Medical on a pro rata basis. The equity interest of the
existing shareholders remains unchanged.
4. “THAT subject to the full compliance of the relevant rules under the Listing Rules of
the Stock Exchange of Hong Kong Limited or any other relevant law and regulation, the
Board be granted with an investment authority to approve an investment with an
investment amount of not more than 30% of the latest audited net asset value of the
Company; or a series of investment within an aggregate period of 12 months with a total
investment amount of not more than 50% of the latest audited net asset value of the
Company.